Novel cancer immunotherapy antibody compositions
Assignees1Globe Biomedical Co., Ltd., 1Globe Health Institute LLC
InventorsCHIANG J. LI, SHYAM UNNIRAMAN, HANNAH BADER, MITHILESH JHA
Life of this patent
Estimating the term…
Abstract
Provided are compositions and methods relating to or derived from anti-PD-L1 antibodies with ADCC and/or CDC activities. More specifically, provided are fully human antibodies that bind PD-L1, PD-L1-binding antibody fragments, derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments.
Claims15
An antigen-binding polypeptide that binds to a human PD-L1 epitope, comprising a heavy chain variable domain and a light chain variable domain, wherein the respective sequences thereof consist essentially of a sequence paring selected from the group consisting of:
- (a) SEQ ID NO:
- 18 and SEQ ID NO:
- 20;
- (b) SEQ ID NO:
- 42 and SEQ ID NO:
- 44;
- and (c) SEQ ID NO:
- 34 and SEQ ID NO:
- 36.
2-5. (canceled)
A method of treating a subject in need thereof for a condition therapeutically, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient, carrier or diluent, and an antigen-binding polypeptide that binds to a human PD-L1 epitope, wherein the polypeptide comprises a heavy chain variable domain and a light chain variable domain, and wherein the respective sequences thereof consist essentially of a sequence paring selected from the group consisting of:
- (a) SEQ ID NO:
- 18 and SEQ ID NO:
- 20;
- (b) SEQ ID NO:
- 42 and SEQ ID NO:
- 44;
- and (c) SEQ ID NO:
- 34 and SEQ ID NO:
- 36.
Dependencies are inferred from the claim text.